Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials

Signal Transduct Target Ther. 2017 Oct 9:2:17054. doi: 10.1038/sigtrans.2017.54. eCollection 2017.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't